Cantourage Group SE

NuWays RecommendationRecommendation
Buy
Price Target
€13.00
Upside
152.92%
Chart
- 1M
- 3M
- 6M
- YTD
- 1Y
- 3Y
€5.14
-€0.18 (-3.38%)
Realtime-Data from 03.07.2025 15:44:14
Cantourage Group SE, founded in Berlin in 2019, is reshaping the medical cannabis market. By uniting global cultivators' expertise with their own industry experience, they simplify import processes for licensed growers. Cantourage handles regulatory complexities, processing raw materials into EU-compliant end products sold through wholesalers and pharmacies. With a network spanning 50 suppliers from 15 countries, they offer a diverse range of high-quality products. In September 2023, Cantourage also launched its own telemedicine platform for medical cannabis, telecan°, to better benefit from Germany’s de-classification of cannabis as a narcotic drug in April 2024.
ISIN
DE000A3DSV01
Market Cap
€64.08M
Enterprise Value
€61.43M
26 week avg vol.
12467479
Primar Exchange
Scale
IPO
2022
Sector
Health Care & Pharma
Headquarters
Berlin, DE
Employees
25
Incorporated
2019
CEO
Philip Schetter
Website
Patrick Hoffmann
22.10%
Florian Holzapfel
21.80%
PiFriva Verwaltungs- und Beteiligungs GmbH
15.80%
Think.Health Projekt M GmbH & Co. KG
11.90%
Axxion SA
1.20%
Free Float
15.60%
31.10.2025
Publication half yearly financial report
KPIs in EUR
KPI | 2024 | 2025e | 2026e |
---|---|---|---|
Sales | 51.42M | 99.97M | 119.03M |
EBITDA | 3.88M | 10.34M | 15.89M |
EBIT | -324.15K | 6.14M | 11.69M |
EPS | -0.02 | 0.34 | 0.66 |
FCF | 1.63M | 3.56M | 6.73M |
Valuation
KPI | 2024 | 2025e | 2026e |
---|---|---|---|
EV / Sales | 1.19x | 0.58x | 0.43x |
EV / EBITDA | 15.85x | 5.60x | 3.22x |
EV / EBIT | (189.51x) | 9.42x | 4.37x |
Price / Earnings | (282.42x) | 14.90x | 7.83x |
EV / FCF | 37.66x | 16.25x | 7.60x |
Downloads
Latest Research
Initiation